- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00038662
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
August 10, 2006 updated by: Abbott
A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Study Overview
Study Type
Interventional
Enrollment
200
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada, G1R 2J6
- Chuq Pavillon Hotel-Dieu
-
-
Alberta
-
Calgary,, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Center
-
Edmonton, Alberta, Canada, T6G1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 1N1
- Cal Andreou, MD
-
Victoria, British Columbia, Canada
- Can-Med Medical Research Inc
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N4K9
- Bruce W. Palmer Urology Inc.
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 4S5
- The Male Health Centres
-
Burlington, Ontario, Canada, L7N 3V2
- Burlington Professional Centre
-
Hamilton,, Ontario, Canada, L8N 1T8
- Hamilton & District Urology Association
-
London, Ontario, Canada, N6A 4G5
- London Health Sciences Centre
-
Markham, Ontario, Canada, L6B1A1
- Quest Clinical Trials
-
North Bay, Ontario, Canada, P1B4Z2
- Guardian Medical Arts Bldg.
-
North York, Ontario, Canada, M6A 3B5
- Jack Barkin, MD
-
Oakville, Ontario, Canada, L6H 3P1
- The Male Health Centres
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook &Women's College Health Sciens Center
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- Hôpital Notre-Dame
-
-
-
-
Alabama
-
Homewood,, Alabama, United States, 35205
- Urology Centers of Alabama
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Alaska Clinical Research Center, LLC
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Urologial Associates, PA
-
-
California
-
La Mesa, California, United States, 91942
- San Diego Urology Center
-
Torrance, California, United States, 90505
- Western Clinical Research Inc
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center
-
-
Florida
-
Fort Myers, Florida, United States, 33916
- Clinical Physiology Associates
-
Tallahassee, Florida, United States, 32308
- Southeastern Urological Center, PA
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-1000
- Johns Hopkins Oncology Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Sheldon Freedman MD
-
Reno, Nevada, United States, 89511
- Nevada Urology Associates
-
Reno, Nevada, United States, 89502
- VA Medical Center(111)
-
-
North Carolina
-
Charlotte,, North Carolina, United States, 28204
- Carolinas Medical Centre
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Tulsa,, Oklahoma, United States, 74104-5433
- Urologic Specialists of Oklahoma, Inc.
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Oregon Urology Specialists
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604-3200
- Urological Assoc. of Lancaster
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh
-
West Reading, Pennsylvania, United States, 19611
- Center for Urologic Care
-
West Reading,, Pennsylvania, United States, 19611
- Center for Urologic Care
-
-
Texas
-
Dallas, Texas, United States, 75230
- nTouch Research Corporation
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Salt Lake Research
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle,, Washington, United States, 98166-3059
- Jeffrey Frankel, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- prostate adenocarcinoma,
- radical prostatectomy,
- PSA between 0.4 and 5 ng/mL,
- PSADT < 1 year
Exclusion Criteria:
- previous hormonal therapy,
- salvage therapy to the pelvis within 3 months prior to randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Darryl Sleep, M.D., Abbott
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Study Registration Dates
First Submitted
June 3, 2002
First Submitted That Met QC Criteria
June 3, 2002
First Posted (Estimate)
June 4, 2002
Study Record Updates
Last Update Posted (Estimate)
August 15, 2006
Last Update Submitted That Met QC Criteria
August 10, 2006
Last Verified
August 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M01-366
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.